ReviewMediators of inflammation2015
Targeting C-Reactive Protein in Inflammatory Disease by Preventing Conformational Changes.
Review in Mediators of inflammation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 95 citations in OpenAlex.
- Dysregulated metabolic homeostasis as a unifying death mechanism underlying the diverse clinical manifestations of COVID-19: insights from a retrospective analysis of sequential blood variables.Frontiers in medicine · 2026Article
- Incidence and risk factors for postoperative pulmonary complications in children following surgery for retroperitoneal neuroblastoma.Frontiers in pediatrics · 2026Article
- Differences in Immunological and Inflammatory Biomarkers Levels in People Infected withAdvanced biomedical research · 2026Article
- Review
- Beyond the Biomarker: Monomeric CRP as a Driver of Multisystem Pathology in Rheumatoid Arthritis.International journal of molecular sciences · 2025Review
- The risk factors for cardiovascular disease and chronic kidney disease in patients with nonalcoholic fatty liver disease in Saudi Arabia.Saudi medical journal · 2025Article
- A Connection Between the Gut Microbiome and Epigenetic Modification in Age-Related Cancer: A Narrative Review.Aging and disease · 2025Review
- Characteristics of primary Sjogren's syndrome with articular manifestations at initial treatment.SAGE open medicine · 2024Article
- Monomeric C-reactive protein: A novel biomarker predicting neurodegenerative disease and vascular dysfunction.Brain pathology (Zurich, Switzerland) · 2023Review
- The Role of Anti-mCRP Autoantibodies in Lupus Nephritis.Kidney diseases (Basel, Switzerland) · 2023Review
- Role of C-Reactive Protein in Kidney Diseases.Kidney diseases (Basel, Switzerland) · 2023Review
- Comprehensive Investigations of Multiple Factors That Are Related to Refractory Outcome in Urosepsis Patients.Yonago acta medica · 2022Article
- What is the optimal time interval between heart catheterization and surgery to prevent acute kidney injury in patients with isolated coronary artery bypass?Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2022Article
- Type 2 Diabetes Induced by Changes in Proteomic Profiling of Zebrafish Chronically Exposed to a Mixture of Organochlorine Pesticides at Low Concentrations.International journal of environmental research and public health · 2022Article
- Seven COVID-19 Patients Treated with C-Reactive Protein (CRP) Apheresis.Journal of clinical medicine · 2022Article
- [CRP apheresis in acute myocardial infarction and COVID-19].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2022Review
- mCRP as a Biomarker of Adult-Onset Still's Disease: Quantification of mCRP by ELISA.Frontiers in immunology · 2022Article
- Glutathione: A Samsonian life-sustaining small molecule that protects against oxidative stress, ageing and damaging inflammation.Frontiers in nutrition · 2022Review
- Monomeric C reactive protein (mCRP) regulates inflammatory responses in human and mouse chondrocytes.Laboratory investigation; a journal of technical methods and pathology · 2021Article
- Dynamic change of blood profile in rat models with acute skin injury artificially infected with methicillin-resistantVeterinary world · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
C-reactive protein (CRP) is a pentraxin that has long been employed as a marker of inflammation in clinical practice. Recent findings brought up the idea of CRP to be not only a systemic marker but also a mediator of inflammation. New studies focused on structural changes of the plasma protein, revealing the existence of two distinct protein conformations associated with opposed inflammatory properties. Native, pentameric CRP (pCRP) is considered to be the circulating precursor form of monomeric CRP (mCRP) that has been identified to be strongly proinflammatory. Recently, a dissociation mechanism of pCRP has been identified on activated platelets and activated/apoptotic cells associated with the amplification of the proinflammatory potential. Correspondingly, CRP deposits found in inflamed tissues have been identified to exhibit the monomeric conformation by using conformation-specific antibodies. Here we review the current literature on the causal role of the dissociation mechanism of pCRP and the genesis of mCRP for the amplification of the proinflammatory potential in inflammatory reactions such as atherosclerosis and ischemia/reperfusion injury. The chance to prevent the formation of proinflammatory mediators in ubiquitous inflammatory cascades has pushed therapeutic strategies by targeting pCRP dissociation in inflammation. In this respect, the development of clinically applicable derivatives of the palindromic compound 1,6-bis(phosphocholine)-hexane (1,6-bis PC) should be a major focus of future CRP research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.